An Fangyu, Jia Xueru, Shi Yangyang, Xiao Xiaolong, Yang Fan, Su Junchang, Peng Xia, Geng Guangqin, Yan Chunlu
Teaching Experiment Training Center, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu, China.
School of Basic Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu, China.
Int Immunopharmacol. 2025 Jan 10;144:113613. doi: 10.1016/j.intimp.2024.113613. Epub 2024 Nov 20.
Osteoporosis is a systemic bone disease characterised by decreased bone mass and a deteriorated bone microstructure, leading to increased bone fragility and fracture risk. Disorders of the intestinal microbiota may be key inducers of osteoporosis. Furthermore, such disorders may contribute to osteoporosis by influencing immune function and lipid metabolism. Therefore, in this review, we aimed to summarise the molecular mechanisms through which the intestinal microbiota affect the onset and development of osteoporosis by regulating Th17/Treg imbalance and lipid metabolism disorders. We also discussed the regulatory mechanisms underlying the effect of intestinal microbiota-related modulators on Th17/Treg imbalance and lipid metabolism disorders in osteoporosis, to explore new molecular targets for its treatment and provide a theoretical basis for clinical management.
骨质疏松症是一种全身性骨病,其特征是骨量减少和骨微结构恶化,导致骨脆性增加和骨折风险升高。肠道微生物群紊乱可能是骨质疏松症的关键诱导因素。此外,此类紊乱可能通过影响免疫功能和脂质代谢而导致骨质疏松症。因此,在本综述中,我们旨在总结肠道微生物群通过调节Th17/Treg失衡和脂质代谢紊乱影响骨质疏松症发生和发展的分子机制。我们还讨论了肠道微生物群相关调节剂对骨质疏松症中Th17/Treg失衡和脂质代谢紊乱影响的调控机制,以探索其治疗的新分子靶点,并为临床管理提供理论依据。